Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 58%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Abivax is a clinical-stage biotechnology company focused primarily on developing a first-in-class modulator of miR-124, obefazimod, for the treatment of inflammatory bowel diseases (IBD). The company's Phase 3 data for obefazimod in ulcerative colitis (UC) showed best-in-disease maintenance efficacy, high rates of endoscopic improvement and remission, and a favorable safety profile. Despite a delay in Phase 2b data for obefazimod in Crohn's disease (CD), the drug's potential efficacy and favorable safety profile, along with a growing patient population in the IBD market, make for a promising outlook on the company's stock.

Bears say

Abivax is facing potential safety concerns with its drug candidate obefazimod due to a higher incidence of malignancies and skin cancer compared to its competitor, Skyrizi. Despite promising efficacy data, the possibility of a black box warning for obefazimod could significantly impact its market share and increase marketing costs. With the potential for regulatory and commercialization delays and competition from emerging therapies, the stock is expected to remain range bound in the near future.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 58% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Jun 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $132.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $132.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.